Immune System News -- ScienceDaily The MYCN oncoprotein plays a key role in starting, advancing and making it difficult to treat various human cancers. When MYCN is overactive, especially in high-risk neuroblastoma, the tumors become less responsive to immunotherapy — a treatment that …
Researchers identified a key metabolite in cells that helps direct immune responses and explains at a single cell level why immune cells that most efficiently recognize pathogens, vaccines, or diseased cells grow and divide faster than other cells. The…
Investigators discovered that unique bacteria colonize the gut shortly after birth and make the neurotransmitter serotonin to educate gut immune cells. This prevents allergic reactions to food and the bacteria themselves during early development.
Researchers have created a DNA origami platform called DoriVac, whose core component is a self-assembling square block-shaped nanostructure. DoriVac vaccines enabled tumor-bearing mice to better control the growth of tumors and to survive significantly…
Making a personalized T cell therapy for cancer patients currently takes at least six months. Scientists have shown that the laborious first step of identifying tumor-reactive T cell receptors for patients can be replaced with a machine learning classi…
A serious immune deficiency in newborns may originate from a system that protects the fetus in utero but lingers too long after birth.
Antibody responses to new SARS-CoV-2 variant infections and vaccinations are powerfully shaped by prior exposures to earlier SARS-CoV-2 vaccines, according to a new study.
Targeting two brain tumor-associated proteins — rather than one — with CAR T cell therapy shows promise as a strategy for reducing solid tumor growth in patients with recurrent glioblastoma (GBM), an aggressive form of brain cancer, according to earl…
Scientists uncovered an overlooked mechanism in the gut immune system of patients suffering from severe cases of Crohn’s disease. The discovery may help define how to treat patients with severe Crohn’s disease.
Studies of interactions between two lab-generated monoclonal antibodies (mAbs) and an essential Epstein-Barr virus (EBV) protein have uncovered targets that could be exploited in designing treatments and vaccines for this extremely common virus.
